PRCT Stock Chart & Stats
$357.00
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$356.00 - $1,217.38
Previous CloseN/A
VolumeN/A
Average Volume (3M)131.00
Market Cap
$16.61B
Enterprise Value$1.25K
Total Cash (Recent Filing)$245.64M
Total Debt (Recent Filing)$51.66M
Price to Earnings (P/E)―
Beta-0.04
Next Earnings
Aug 04, 2026EPS Estimate
-8.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.82
Shares Outstanding56,918,842
10 Day Avg. Volume0
30 Day Avg. Volume131
Financial Highlights & Ratios
PEG Ratio10.67
Price to Book (P/B)4.78
Price to Sales (P/S)5.67
P/FCF Ratio-29.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth / AdoptionConsistent double-digit top-line growth and FY26 guidance (~27–33%) reflect accelerating Aquablation adoption and system placements. A growing installed base supports recurring per-procedure consumable revenue and creates durable revenue leverage as procedure volumes scale over the next several quarters.
High Gross Margins / Unit EconomicsSustained ~64–65% gross margins demonstrate strong unit economics driven by high-margin consumables and favorable pricing. This margin profile provides structural cushion for commercial investment, improving the path to profitability if procedure volumes and handpiece uptake continue to scale.
Clinical And Regulatory MomentumAn EAU guideline upgrade and FDA clearance for AI assistance materially strengthen clinical credibility and differentiation. Those endorsements reduce adoption friction with hospitals and payors, supporting sustained procedure growth, broader guideline-based referrals, and durable market share gains.
Bears Say
Persistent Losses And Negative Cash FlowTTM operating margin near -30% and continued negative operating and free cash flow indicate the business still consumes significant capital to grow. Structural losses mean reliance on either rapid volume/margin acceleration or sustained external funding; either outcome creates execution and financing risk in the medium term.
Reliance On Cash ReservesWhile $249M provides runway for expansion and trials, sizable quarterly EBITDA losses and persistent negative FCF mean the company remains dependent on that liquidity or new capital. Missed revenue/margin targets would shorten runway and likely necessitate external financing or cost cuts, increasing dilution or operational disruption.
Tariff And Cost HeadwindsRising tariff costs and elevated operating expenses create a structural drag on margins and cash generation. Management flags much of the commercial benefit as back‑loaded, so cost volatility and execution timing risk could delay the anticipated EBITDA inflection and pressure near‑term profitability and liquidity.
PRCT FAQ
What was Procept Biorobotics Corp.’s price range in the past 12 months?
Procept Biorobotics Corp. lowest stock price was $356.00 and its highest was $1217.38 in the past 12 months.
What is Procept Biorobotics Corp.’s market cap?
Procept Biorobotics Corp.’s market cap is $16.61B.
When is Procept Biorobotics Corp.’s upcoming earnings report date?
Procept Biorobotics Corp.’s upcoming earnings report date is Aug 04, 2026 which is in 9 days.
How were Procept Biorobotics Corp.’s earnings last quarter?
Procept Biorobotics Corp. released its earnings results on Apr 29, 2026. The company reported -$9.805 earnings per share for the quarter, beating the consensus estimate of -$9.857 by $0.053.
Is Procept Biorobotics Corp. overvalued?
According to Wall Street analysts Procept Biorobotics Corp.’s price is currently Undervalued.
Does Procept Biorobotics Corp. pay dividends?
Procept Biorobotics Corp. does not currently pay dividends.
What is Procept Biorobotics Corp.’s EPS estimate?
Procept Biorobotics Corp.’s EPS estimate is -8.11.
How many shares outstanding does Procept Biorobotics Corp. have?
Procept Biorobotics Corp. has 56,918,842 shares outstanding.
What happened to Procept Biorobotics Corp.’s price movement after its last earnings report?
Procept Biorobotics Corp. reported an EPS of -$9.805 in its last earnings report, beating expectations of -$9.857. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Procept Biorobotics Corp.?
Currently, no hedge funds are holding shares in MX:PRCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PROCEPT BioRobotics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.77%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.22%
Trailing 12-Months
Company Description
Procept Biorobotics Corp.
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.